Evidence map›Paper›PMID 36602360›Full record

ArticleJournal of clinical microbiology2023

Performance Evaluation of the BACTEC MGIT 960 System for Rifampin Drug-Susceptibility Testing of Mycobacterium tuberculosis Using the Current WHO Critical Concentration.

Hui-Jin Yu, Tae Yeul Kim, Gangmin Kim, Hyang Jin Shim, On Kyun Kang, Seungmo Kim, Chang-Ki Kim, Byung Woo Jhun, Nam Yong Lee, Hee Jae Huh and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hui-Jin Yu *Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Tae Yeul Kim *Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0002-6405-5305
Gangmin KimSungkyunkwan University School of Medicine, Suwon, South Korea.
Hyang Jin ShimCenter for Clinical Medicine, Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
On Kyun KangDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Seungmo KimKorean National Tuberculosis Association, Korean Institute of Tuberculosis, Cheongju, South Korea.
Chang-Ki KimDepartment of Laboratory Medicine, Seoul Clinical Laboratories, Yongin, South Korea.
Byung Woo JhunDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0002-6348-8731
Nam Yong LeeDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hee Jae HuhDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0001-8999-7561
Hee Joo LeeKorean National Tuberculosis Association, Seoul, Korea.
Samsung Medical Center · KRKorea National Tuberculosis Association · KRSeoul Medical Center · KRSungkyunkwan University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization recently lowered the rifampin (RIF) critical concentration (CC) for drug-susceptibility testing (DST) of Mycobacterium tuberculosis complex (MTBC) using the mycobacterial growth indicator tube (MGIT) 960 system. Here, we evaluated the diagnostic performance of the MGIT system with the revised CC for determining MTBC RIF resistance with 303 clinical MTBC isolates, including 122 isolates with

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsDNA-Directed RNA PolymerasesDrug Evaluation, PreclinicalHumansMicrobial Sensitivity TestsMutationRifampinAntitubercular AgentsDNA-Directed RNA PolymerasesRifampincritical concentrationMycobacterial Growth Indicator TubeMycobacterium tuberculosisrifampinrpoBsusceptibility

Identifiers

PMID36602360
PMCPMC9879093
OpenAlexW4313545484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.